Novasome

What Novasome does

Novasome (Centrum Badawczo-Rozwojowe Novasome Sp. z o.o.) is a Wrocław-based contract research organization founded in 2004 as a spin-off from a Wrocław academic consortium, now operating as part of Grupa Hasco. The company delivers pharmaceutical R&D services across four service lines: research and development (medicinal product, dietary supplement, and cosmetic formulation, preformulation/deformulation, stability studies, registration documentation); analytical studies (chromatography, particle characterization, X-ray diffraction, thermal analysis, dissolution testing); technological tasks (tablet manufacturing, granulation, mixing/homogenization, coating, packaging); and GMP quality control testing. Service delivery rests on a capital-intensive equipment park that includes HPLC/GC-MS systems, a WITec Alpha 300R confocal Raman microscope, Mastersizer and Zetasizer particle analyzers, XRPD X'Pert3 with TGA/DSC, ICH-compliant stability chambers, and specialized dissolution apparatus, operated by PhD-level scientific staff.

The business model is professional-services based, with quote-based pricing customized to individual client projects and a horizontal customer segmentation covering pharmaceutical companies (primary), dietary supplement manufacturers (primary), cosmetics companies (primary), and academic/research institutions (secondary). Distribution is direct B2B with strategic consortium partnerships, notably with PPF Hasco-Lek S.A. (a related Grupa Hasco entity) and Pikralida. Beyond contract services, the company has developed and licensed numerous proprietary products — including Biotylek, LizyMax, Hascovir Lipożel Pro, DIH, Furaginum Hasco, Ketokaps Max, and Mel Max Actigel — that are commercialized through the Hasco-Lek portfolio.

Novasome's competitive positioning rests on three rare Polish regulatory designations: R&D Centre (CBR) status since 2014, GMP certification since 2017, and scientific unit status since 2018, augmented by specialized manufacturing permits for narcotic substances (cannabis, THC, phenobarbital) and category 1 precursors. The firm has won multiple Polish business awards (Diament Forbes 2016, Gazele Biznesu 2015, Gepard Biznesu 2015, Efektywna Firma 2015, Mocna Firma Godna Zaufania 2015) and was identified by an ASM market study as the leader in R&D potential in Lower Silesia. EU/public grant funding totaling approximately PLN 9.2M across 2008, 2016-17, 2021-23, and 2025 rounds has materially subsidized infrastructure development and capability expansion, including a PLN 5.77M API synthesis pilot line project with Pikralida (2021-2023).

Name

Novasome

Legal name

Centrum Badawczo-Rozwojowe Novasome Sp. z o.o.

Website

https://novasome.pl

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Wrocław-based pharmaceutical contract research organization (part of Grupa Hasco) providing formulation R&D, analytical testing, GMP quality control, and technology transfer services for pharmaceutical, dietary supplement, and cosmetics companies, with proprietary product development commercialized through Hasco-Lek.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Research & Development

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

akta.pro secondary industries

Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical R&D services
• Analytical testing services
• Contract research organization
• GMP quality control
• Formulation development

Headquarters

HQ city

Wroclaw

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Contract R&D Services: Research and development services provided to pharmaceutical, dietary supplement, and cosmetics companies including formulation development, analytical method development, preformulation/deformulation studies, and technology transfer.
2. Analytical Testing Services: Comprehensive analytical services including chromatographic analyses, particle characterization, X-ray analysis, release studies, and stability testing performed under GMP conditions.
3. GMP Quality Control Testing: Contract manufacturing quality control testing for medicinal products and starting materials, performed under quality-contractual agreements for external pharmaceutical companies.
4. Technology Transfer Services: Transfer of developed methods and technologies to client's target manufacturing sites, including documentation and implementation support.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Novasome operates a contract research organization providing pharmaceutical R&D services from preformulation through technology transfer. Core service lines include R&D Services (medicinal product, dietary supplement, and cosmetic development), Analytical Studies (chromatography, particle characterization, X-ray, stability, release testing), Technological Tasks (tablet manufacturing, granulation, mixing), and GMP Quality Control testing. The company also develops proprietary formulations commercialized through the Hasco-Lek portfolio.

Product overview

Novasome is a Research and Development Centre (CBR) providing comprehensive R&D services for medicinal products, dietary supplements, and cosmetics. The company operates as a service-based organization offering four core service lines: (1) R&D Services covering product development from formulation through registration documentation; (2) Analytical Studies including chromatography, spectroscopy, particle analysis, and stability testing; (3) Technological Tasks for manufacturing tablets, granules, creams, gels, and other pharmaceutical forms; and (4) GMP System for quality control testing. In addition to services, Novasome has developed multiple proprietary products commercialized through the Hasco-Lek portfolio, including Biotylek, Biotylek Max, LizyMax, Viruzine Forte, Hascovir Lipożel Pro, Hascoderm, Zatomed, Ketokaps Max, DIH line, Allefin, Furaginum Hasco, Ferovit, Natussic, Paracetamol Hasco Forte, Witamina C Liposomal, Mel Max Actigel, and Clobetaxon.

Differentiator

Problem solved

Functional benefit

Products and services

• R&D Services Comprehensive R&D services including medicinal product development, supplement and cosmetic development, analytical methods development and validation, preformulation/deformulation studies, stability studies, and registration documentation preparation. For pharmaceutical, dietary supplement, and cosmetics companies.
• Analytical Studies Services Wide range of analytical services including chromatographic analyses (HPLC, GC), spectrophotometric analyses, titration analyses, thermogravimetry (TGA), DSC, X-ray analyses, particle size and shape analysis, water sorption analysis, and drug release testing. For pharmaceutical, supplement, and cosmetics manufacturers.
• Technological Tasks Services Manufacturing services including mixing of dry forms, mixing and homogenization of liquid and semi-solid forms, granulation of powders, tablet manufacturing, coating, and packaging. For pharmaceutical and related product manufacturers.
• GMP System Services Quality control testing services under Good Manufacturing Practice system including physico-chemical testing of medicinal products and starting materials, with permits for narcotic substances (cannabis, tetrahydrocannabinols, phenobarbital) and category 1 precursors (pseudoephedrine, ephedrine). For pharmaceutical manufacturers.

Quantifiable outcome

• Only 53 enterprises in Poland held R&D centre status as of 2021, demonstrating elite positioning.
• +1 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Nine partnerships are on record, tiered core, minor and major.

• PPF Hasco-Lek S.A.coreStrategic or Co-development Partner · 10 January 2023Novasome received funding from the Agency for Medical Research alongside PPF Hasco-Lek S.A. for developing a complex generic product for type 2 diabetes treatment. The product combines two active substances from the SGLT2 inhibitors (flozyn) group and biguanides, with bioavailability to be confirmed in clinical trials according to EMA standards.
• Polish Chamber of Chemical Industry (PCCI)minorStrategic or Co-development Partner · 22 April 2022Membership enables partnerships with chemical industry representatives with expertise in coordinating chemical R&D. Novasome's new focus on active ingredient synthesis contributes to API supply chain stability in the EU market.
• LifeScience Cluster KrakówmajorStrategic or Co-development Partner · 14 December 2021Novasome joined as partner in December 2021. The cluster supports enterprises, institutions and universities in developing innovativeness and entrepreneurship in life sciences. Membership provides access to larger client network and positions Novasome as reliable partner in pharmaceutical, cosmetics, chemical and veterinary medicine sectors.
• PikralidacoreStrategic or Co-development Partner · 1 July 2021Consortium partnership for POIR.01.01.01-0072-21 project to develop innovative pilot line for API synthesis. Total project budget of PLN 9.58 million with PLN 5.77 million EU funding. Project duration July 2021 to December 2023, aiming to ensure pharmaceutical sovereignty in the EU.
• Nutribiomed ClustermajorStrategic or Co-development Partner · 1 January 2016National Key Cluster membership since 2016. Cluster focuses on dietary supplements, nutraceuticals and biomedical products, promoting use of local natural raw materials and modern technologies. Novasome provides R&D support to cluster members.
• University of WrocławcoreStrategic or Co-development PartnerOngoing cooperation with Faculty of Chemistry for collaborative research, student internships, master's theses, and industrial doctorate programs. Partnership supports innovation and talent development in organic synthesis.
• Wroclaw University of Life SciencesmajorStrategic or Co-development PartnerRegular collaboration with university research teams, contributing to interdisciplinary R&D projects in pharmaceutical sciences.
• Wroclaw Medical UniversitymajorStrategic or Co-development PartnerCooperation with university for medical and pharmaceutical research projects, leveraging clinical and pharmacological expertise.
• Partnerstwo dla Innowacji (Partnership for Innovation)minorStrategic or Co-development PartnerEmployers' Association supporting entrepreneurs with R&D centre status in technological advancement. Association advocates for public-private partnerships to support Polish enterprise goals.

Scale indicators13 records

Recent moves15 records

Expansion highlights6 records

Direct peers

• Selvita: Poland-based contract research organization offering drug discovery, medicinal chemistry, and pharmaceutical R&D services. Directly comparable to Novasome as a Polish-headquartered mid-size CRO with overlap in formulation, analytical, and CMC services for pharma clients.
• Pikralida: Polish CRO focused on pharmaceutical R&D, analytical services, and API synthesis. Direct consortium partner of Novasome on the EU-funded POIR.01.01.01-0072-21 API synthesis project, with comparable services in preformulation, analytical method development, and small-molecule CMC.

Regional players

• Polpharma: Poland's largest pharmaceutical manufacturer with in-house R&D, API production, and formulation development. Regional peer/ecosystem participant that sits in the same Polish pharma value chain where Novasome delivers formulation, analytical, and technology transfer services.
• Celon Pharma: Polish integrated pharmaceutical company with proprietary drug development, formulation, and manufacturing capabilities. Comparable as a Poland-based pharma R&D operator in the same therapeutic and formulation domains Novasome services from its Wrocław lab.

Broad incumbents

• Eurofins Scientific: Global testing laboratory network providing pharmaceutical analytical services, stability, particle characterization, and GMP QC testing. Overlaps with Novasome's analytical and GMP QC service lines at higher throughput and broader geographic reach.
• QPS Holdings: Mid-size global CRO with bioanalytical, CMC, formulation, and GMP services. Comparable as a mid-tier CRO/CDMO offering overlapping analytical, formulation, and quality testing services that compete for similar mid-market pharma sponsors.
• Charles River Laboratories: Global CRO/CDMO offering formulation development, analytical services, GMP testing, and CMC support across small molecules and biologics. Broad incumbent that competes with Novasome for analytical, formulation, and quality control outsourcing work from mid-market European pharma.
• ICON plc: Global CRO providing outsourced development and commercialization services to pharma. Broad incumbent benchmark for what scaled-up CRO operating models look like, even though its primary focus on clinical trials differs from Novasome's pre-clinical and CMC orientation.

Emerging players

• Mabion: Polish biopharmaceutical CDMO focused on biologics development and manufacturing. Adjacent peer in the Polish CDMO landscape, sharing GMP-certified analytical infrastructure and EU grant-backed growth, though focused on biologics rather than small molecules.
• ICHEM: Polish CDMO offering contract development and GMP manufacturing for APIs and intermediates. Comparable to Novasome's API synthesis and small-molecule CMC ambitions, particularly relevant given Poland's push for API sovereignty under EU funding programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookpl-pl.facebook.com/GrupaHasco
• LinkedInlinkedin.com/company/cbr-novasome

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novasome